Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink.
Autoimmune Diseases
/ physiopathology
Case-Control Studies
Databases, Factual
Disease Progression
Female
Fever
/ chemically induced
Follow-Up Studies
Humans
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ prevention & control
Male
Patient Safety
/ statistics & numerical data
Primary Health Care
/ methods
Reference Values
Referral and Consultation
/ statistics & numerical data
Rheumatic Diseases
/ immunology
Risk Management
Vaccination
/ adverse effects
Vaccines, Inactivated
/ administration & dosage
Vasculitis
/ chemically induced
autoimmune diseases
rheumatoid arthritis
vaccination
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
17
01
2019
revised:
25
03
2019
accepted:
07
04
2019
pubmed:
1
5
2019
medline:
13
3
2020
entrez:
1
5
2019
Statut:
ppublish
Résumé
ObjectivesTo examine the association between inactivated influenza vaccine (IIV) administration and primary care consultation for joint pain, rheumatoid arthritis (RA) flare, corticosteroid prescription, vasculitis and unexplained fever in people with autoimmune rheumatic diseases (AIRDs). We undertook within-person comparisons using self-controlled case-series methodology. AIRD cases who received the IIV and had an outcome of interest in the same influenza cycle were ascertained in Clinical Practice Research Datalink. The influenza cycle was partitioned into exposure periods (1-14 days prevaccination and 0-14, 15-30, 31-60 and 61-90 days postvaccination), with the remaining time-period classified as non-exposed. Incidence rate ratios (IRR) and 95% CI for different outcomes were calculated. Data for 14 928 AIRD cases (69% women, 80% with RA) were included. There was no evidence for association between vaccination and primary care consultation for RA flare, corticosteroid prescription, fever or vasculitis. On the contrary, vaccination associated with reduced primary care consultation for joint pain in the subsequent 90 days (IRR 0.91 (95% CI 0.87 to 0.94)). This study found no evidence for a significant association between vaccination and primary care consultation for most surrogates of increased disease activity or vaccine adverse-effects in people with AIRDs. It adds to the accumulating evidence to support influenza vaccination in AIRDs.
Identifiants
pubmed: 31036623
pii: annrheumdis-2019-215086
doi: 10.1136/annrheumdis-2019-215086
pmc: PMC6691866
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1122-1126Subventions
Organisme : Versus Arthritis
ID : 21297
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0617-20005
Pays : United Kingdom
Organisme : Department of Health
ID : RP_2014-04-026
Pays : United Kingdom
Organisme : Arthritis Research UK
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: CDM is funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care West Midlands, the NIHR School for Primary Care Research and an NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). JSN-V-T acknowledges funding from the NIHR Biomedical Research Centre (acute respiratory infections), MD and AA acknowledge funding from the NIHR Biomedical Research Centre (musculoskeletal theme) Nottingham. Potential conflicts of interest: JSN-V-T is currently on secondment to the Department of Health and Social Care, England (DHSC). The views expressed in this paper are those of the authors and do not necessarily represent those of the National Health Service, NIHR or DHSC. All other authors have declared no conflicts of interest.
Références
Ann Rheum Dis. 2003 Jul;62(7):685
pubmed: 12810440
Rheumatology (Oxford). 2003 Jul;42(7):907-9
pubmed: 12826713
N Engl J Med. 2004 Dec 16;351(25):2611-8
pubmed: 15602021
Stat Med. 2006 May 30;25(10):1768-97
pubmed: 16220518
J Clin Rheumatol. 2009 Sep;15(6):289-91
pubmed: 19734734
Ann Rheum Dis. 2010 Oct;69(10):1831-3
pubmed: 20603497
J Gen Intern Med. 2011 May;26(5):546-50
pubmed: 21203857
BMC Musculoskelet Disord. 2012 Aug 27;13:158
pubmed: 22925480
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26
pubmed: 24339395
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Vaccine. 2015 Jul 17;33(31):3703-8
pubmed: 26073016
Rheumatol Int. 2016 Sep;36(9):1255-63
pubmed: 27372078
Rheum Dis Clin North Am. 2017 Feb;43(1):15-26
pubmed: 27890171
Ann Rheum Dis. 2017 Sep;76(9):1559-1565
pubmed: 28468794
Curr Rheumatol Rev. 2017;13(3):188-196
pubmed: 28521688
Ann Rheum Dis. 2018 Jun;77(6):898-904
pubmed: 29572291
Int J Rheum Dis. 2018 Jun;21(6):1246-1253
pubmed: 29879317
Rheumatology (Oxford). 2018 Oct 1;57(10):1726-1734
pubmed: 29901743
Clin Diagn Lab Immunol. 1997 Jul;4(4):491-2
pubmed: 9220171